Nateglinide

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 22, 2000	StarlixNDA 21204 · New molecular entity	Novartis	16	Discontinued
Sep 9, 2009	NateglinideANDA 77461	Dr Reddys Labs Ltd	4	Marketed
Sep 9, 2009	NateglinideANDA 77463	Strides Pharma Intl	5	Marketed
Mar 30, 2011	NateglinideANDA 77462	Watson Labs	3	Marketed
Dec 11, 2015	NateglinideANDA 205055	Alvogen	2	Discontinued
Jul 6, 2016	NateglinideANDA 205248	Zydus Pharms	3	Marketed
Jun 18, 2018	NateglinideANDA 205544	Rising	1	Marketed
Apr 19, 2019	NateglinideANDA 206432	Cadila Pharms Ltd	1	Marketed
—	NateglinideANDA 77467	Teva Pharms	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA